Literature DB >> 8608046

The cost of managing lung cancer in Canada.

W K Evans1, B P Will, J M Berthelot, M C Wolfson.   

Abstract

The POpulation HEalth Model (POHEM) lung cancer microsimulation model has provided a useful framework for calculating the cost of managing individual cases of lung cancer in Canada by stage, cell type, and treatment modality, as well as the total economic burden of managing all cases of lung cancer diagnosed in Canada. These data allow an estimation of the overall cost effectiveness of lung cancer therapy. the model also provides a frame-work for evaluating the cost effectiveness of new therapeutic strategies, such as combined modality therapy for stage III disease or new chemotherapy drugs for stage IV disease. By expressing the cost of lung cancer treatment as cost of life-years gained, such analyses allows useful comparisons of the cost effectiveness of these treatments with those of other costly but accepted medical therapies.

Entities:  

Mesh:

Year:  1995        PMID: 8608046

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  4 in total

1.  Management and costs of treating lung cancer patients in a university hospital.

Authors:  Konstantin J Dedes; Thomas D Szucs; Stephan Bodis; Markus Joerger; Adam Lowy; Erich W Russi; Hans C Steinert; Walter Weder; Rolf A Stahel
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

2.  The hospital costs of treating lung cancer in the United Kingdom.

Authors:  J L Wolstenholme; D K Whynes
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

3.  Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.

Authors:  C C Earle; W K Evans
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

4.  End-of-Life Health-Care Cost of Patients With Lung Cancer: A Retrospective Study.

Authors:  Kyriakos Souliotis; Chara Kani; Androniki Marioli; Aggeliki Kamboukou; Aikaterini Prinou; Konstantinos Syrigos; Sophia Markantonis
Journal:  Health Serv Res Manag Epidemiol       Date:  2019-04-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.